Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2013 09:00 ET | Source: Tufts Center for the Study of Drug Development

New Protocol Design Approaches Will Improve Clinical Trial Performance and Efficiency, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwired - Apr 9, 2013) - Growing protocol complexity -- responsible for longer clinical study times, greater difficulty in recruiting volunteers, and rising drug development costs...
March 12, 2013 09:00 ET | Source: Tufts Center for the Study of Drug Development

Investigative Site Landscape Remains Highly Fragmented as the Number of Active Investigators Worldwide Reaches an All-Time High, According to the Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwire - Mar 12, 2013) - More than half of all clinical trials worldwide that are regulated by the U.S. Food and Drug Administration (FDA) were conducted by independent,...
January 24, 2013 09:00 ET | Source: Tufts Center for the Study of Drug Development

Companion Diagnostics, Key to Development of Personalized Medicines, Face Hurdles, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwire - Jan 24, 2013) - Companion diagnostics, which are central to the creation of personalized medicines, have captured the interest of many drug companies, but face a number of...
January 15, 2013 09:00 ET | Source: Tufts Center for the Study of Drug Development

New Research From Tufts Center for the Study of Drug Development Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices

BOSTON, MA--(Marketwire - Jan 15, 2013) - While nine out of 10 clinical trials worldwide meet their patient enrollment goals, reaching those targets typically means that drug developers need to...
January 08, 2013 09:00 ET | Source: Tufts Center for the Study of Drug Development

Drug Developers Need to More Fully Identify and Address Root Causes of R&D Inefficiency, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwire - Jan 8, 2013) - While patent expirations on many top selling medicines are spurring the research-based drug industry to embrace new development paradigms to replenish...
November 06, 2012 09:00 ET | Source: Tufts Center for the Study of Drug Development

Extraneous Data Collected in Clinical Trials Cost Drug Developers $4 Billion to $6 Billion Annually, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwire - Nov 6, 2012) - One out of every five procedures performed during later stage clinical trials collects extraneous data and costs drug developers more than $1 million per...
October 17, 2012 09:00 ET | Source: Tufts Center for the Study of Drug Development

Contract Support and Technical Service Providers Expected to Play a Growing Role in Drug Development, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwire - Oct 17, 2012) - Drug sponsors and their contract service providers are using more sophisticated, integrated, and coordinated relationship structures to deliver greater...
September 05, 2012 09:00 ET | Source: Tufts Center for the Study of Drug Development

Oncology Drugs Get Faster Approvals Than Non-Oncology Drugs in U.S., but the Opposite Is True in the EU, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwire - Sep 5, 2012) - Approval times for new oncology drugs in the United States during the last decade were shorter than approval times for non-oncology products, while the...
August 07, 2012 09:00 ET | Source: Tufts Center for the Study of Drug Development

Drug Companies Are Teaming With Academic Medical Centers to Create New Medicines, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwire - Aug 7, 2012) - Drug developers are forging new ways to work with academic medical centers to create the next generation of breakthrough medicines, which is changing the...
July 10, 2012 09:00 ET | Source: Tufts Center for the Study of Drug Development

U.S. Cancer Patients Get Faster Access to More Oncology Drugs Than European Patients, According to Tufts Center for the Study of Drug Development

BOSTON, MA--(Marketwire - Jul 10, 2012) - Cancer patients in the United States get faster access to more oncology drugs to treat their disease than patients in Europe, according to a newly...